Non-Small Cell Lung Cancer Market By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others), By Treatment Type (Chemotherapy, Radiotherapy, Surgery, Targeted Therapy, Immunotherapy, Combination Therapy, Others), By Therapeutic Area (First-Line Therapy, Second-Line Therapy, Adjuvant Therapy), By End-user (Hospitals, Cancer Centers, Ambulatory Surgical Centers, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025 – 2035.

Published Date: Mar 2025 | Report ID: MI2347 | 215 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Type

  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Adenocarcinoma
  • Others

By Treatment Type

  • Chemotherapy
  • Radiotherapy
  • Surgery
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapy
  • Others

By Therapeutic Area

  • First-Line Therapy
  • Second-Line Therapy
  • Adjuvant Therapy

By End-user

  • Hospitals
  • Cancer Centers
  • Ambulatory Surgical Centers 
  • Others

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

List of Companies:

  • Bristol Myers Squibb
  • Roche
  • Merck & Co.
  • AstraZeneca
  • Novartis
  • Pfizer
  • Eli Lilly and Company
  • Johnson & Johnson
  • Amgen
  • Sanofi
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceuticals
  • Bayer
  • GSK (GlaxoSmithKline)
  • BeiGene

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing